PRIME THERAPEUTICS for PRIME THERAPEUTICS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior and on the important role PBMs play in holding down drug costs; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164 - Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3 - Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, H.R. 3684/ P.L. 117-58, Infrastructure Investment Act, provisions related to the repeal of a rule repealing the safeharbor for drug rebate; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; repeal of the rebate rule and audit/transparency provisions on PBMs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Medicare/Medicaid MMM
Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164 - Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3 - Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, H.R. 3684/ P.L. 117-58, Infrastructure Investment Act, provisions related to the repeal of a rule repealing the safeharbor for drug rebate; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.